Joanna Van Elk

494 total citations
7 papers, 341 citations indexed

About

Joanna Van Elk is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Joanna Van Elk has authored 7 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Oncology and 2 papers in Genetics. Recurrent topics in Joanna Van Elk's work include Phagocytosis and Immune Regulation (4 papers), CAR-T cell therapy research (4 papers) and HIV Research and Treatment (2 papers). Joanna Van Elk is often cited by papers focused on Phagocytosis and Immune Regulation (4 papers), CAR-T cell therapy research (4 papers) and HIV Research and Treatment (2 papers). Joanna Van Elk collaborates with scholars based in United States, United Kingdom and Netherlands. Joanna Van Elk's co-authors include David A. Sallman, Mark P. Chao, Paresh Vyas, Chris H. Takimoto, Rami S. Komrokji, Guido Marcucci, Adam S. Asch, Suman Kambhampati, William B. Donnellan and Jens-Peter Volkmer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Academy of Dermatology.

In The Last Decade

Joanna Van Elk

7 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joanna Van Elk United States	6	194	143	120	70	37	7	341
Yoshinari Kawabata Japan	9	182 0.9×	196 1.4×	96 0.8×	129 1.8×	13 0.4×	19	415
Rupa Narayan United States	11	107 0.6×	126 0.9×	134 1.1×	119 1.7×	51 1.4×	34	350
Kiyoshi Okazuka Japan	11	180 0.9×	87 0.6×	160 1.3×	108 1.5×	21 0.6×	36	340
Cynthia Schultz United States	10	144 0.7×	121 0.8×	167 1.4×	36 0.5×	21 0.6×	12	339
Carmen Herrero-Sánchez Spain	7	204 1.1×	132 0.9×	121 1.0×	63 0.9×	28 0.8×	8	346
M A Kharfan-Dabaja United States	10	235 1.2×	77 0.5×	50 0.4×	85 1.2×	64 1.7×	24	322
Miori Inoue Japan	7	121 0.6×	74 0.5×	241 2.0×	102 1.5×	30 0.8×	10	365
Takahide Ara Japan	9	159 0.8×	107 0.7×	69 0.6×	93 1.3×	62 1.7×	54	324
Etsuko Aoki United States	8	136 0.7×	58 0.4×	174 1.4×	54 0.8×	43 1.2×	16	364
Emilie C. Bright United States	11	352 1.8×	446 3.1×	52 0.4×	86 1.2×	22 0.6×	24	589

Countries citing papers authored by Joanna Van Elk

Since Specialization

Citations

This map shows the geographic impact of Joanna Van Elk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna Van Elk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna Van Elk more than expected).

Fields of papers citing papers by Joanna Van Elk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanna Van Elk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna Van Elk. The network helps show where Joanna Van Elk may publish in the future.

Co-authorship network of co-authors of Joanna Van Elk

This figure shows the co-authorship network connecting the top 25 collaborators of Joanna Van Elk. A scholar is included among the top collaborators of Joanna Van Elk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna Van Elk. Joanna Van Elk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Affandi, Alsya J., Joanna Van Elk, Janneke J. Maaskant, et al.. (2024). Development of a Versatile Cancer Vaccine Format Targeting Antigen-Presenting Cells Using Proximity-Based Sortase A-Mediated Ligation of T-Cell Epitopes. Bioconjugate Chemistry. 35(11). 1805–1814. 3 indexed citations

Sallman, David A., Monzr Al Malki, Adam S. Asch, et al.. (2020). Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.. Journal of Clinical Oncology. 38(15_suppl). 7507–7507. 70 indexed citations

Sallman, David A., Will Donnellan, Adam Asch, et al.. (2019). S878 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS. HemaSphere. 3(S1). 394–394. 9 indexed citations

Sallman, David A., Adam S. Asch, Monzr M. Al Malki, et al.. (2019). The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. Blood. 134(Supplement_1). 569–569. 164 indexed citations

Sallman, David A., William B. Donnellan, Adam S. Asch, et al.. (2019). The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.. Journal of Clinical Oncology. 37(15_suppl). 7009–7009. 53 indexed citations

Stricker, Raphael B., et al.. (1994). Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene. Journal of the American Academy of Dermatology. 31(3). 462–466. 15 indexed citations

Stricker, Raphael B., Joanna Van Elk, Timothy G. Berger, et al.. (1993). Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection. Immunology Letters. 36(1). 1–6. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact